Deutsche Bank Ag\ Poseida Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 31,868 shares of PSTX stock, worth $86,999. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,868

Previous 24,275 31.28%

Holding current value

$86,999

Previous $70,000 30.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$2.7 - $4.04 $20,501 - $30,675	7,593 Added 31.28%	31,868 $91,000
Q2 2024 Aug 14, 2024	SELL	$2.0 - $3.46 $10,752 - $18,600	-5,376 Reduced 18.13%	24,275 $70,000
Q1 2024 May 15, 2024	BUY	$2.76 - $4.13 $81,836 - $122,458	29,651 New	29,651 $94,000
Q3 2023 Nov 09, 2023	BUY	$1.62 - $2.79 $58,125 - $100,105	35,880 New	35,880 $85,000
Q2 2022 Aug 11, 2022	SELL	$1.87 - $5.0 $29,207 - $78,095	-15,619 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.22 - $7.04 $5,982 - $13,080	-1,858 Reduced 10.63%	15,619 $70,000
Q4 2021 Feb 11, 2022	BUY	$6.23 - $7.6 $5,818 - $7,098	934 Added 5.65%	17,477 $119,000
Q3 2021 Nov 04, 2021	SELL	$7.09 - $10.71 $3,771 - $5,697	-532 Reduced 3.12%	16,543 $121,000
Q2 2021 Aug 11, 2021	SELL	$7.96 - $10.07 $39,004 - $49,343	-4,900 Reduced 22.3%	17,075 $171,000
Q1 2021 May 13, 2021	BUY	$8.51 - $11.91 $96,562 - $135,142	11,347 Added 106.77%	21,975 $209,000
Q4 2020 Feb 16, 2021	BUY	$8.29 - $11.7 $32,297 - $45,583	3,896 Added 57.87%	10,628 $117,000
Q3 2020 Nov 12, 2020	BUY	$8.09 - $16.25 $54,461 - $109,395	6,732 New	6,732 $60,000

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.5M

Call Options Held

377K

Put Options Held

22.2K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $234M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account